Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 263 JPY -1.09%
Market Cap: 34.7B JPY
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

0
Revenue
+0%
Growth Rates:
1 Year
+3%
3 Years
+5%
5 Years
+7%
7 Years
+21%
10 Years
+46%
0
Operating Income
+0%
Growth Rates:
1 Year
-34%
3 Years
-51%
5 Years
-39%
7 Years
-23%
10 Years
-3%
0
Net Income
+0%
Growth Rates:
1 Year
-22%
3 Years
-42%
5 Years
-31%
7 Years
-6%
10 Years
+32%

Earnings Waterfall
Daito Pharmaceutical Co Ltd

Revenue
47.4B JPY
Cost of Revenue
-38.3B JPY
Gross Profit
9B JPY
Operating Expenses
-6B JPY
Operating Income
3.1B JPY
Other Expenses
-425m JPY
Net Income
2.7B JPY

Income Statement
Daito Pharmaceutical Co Ltd

Rotate your device to view
Income Statement
Currency: JPY
Millions
Ones
Thousands
Millions
Billions
TTM
Quarterly
Annual
TTM
Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Feb-2016 May-2016 Aug-2016 Nov-2016 Feb-2017 May-2017 Aug-2017 Nov-2017 Feb-2018 May-2018 Aug-2018 Nov-2018 Feb-2019 May-2019 Aug-2019 Nov-2019 Feb-2020 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Aug-2021 Nov-2021 Feb-2022 May-2022 Aug-2022 Nov-2022 Feb-2023 May-2023 Aug-2023 Nov-2023 Feb-2024 May-2024 Aug-2024 Nov-2024
Revenue
Revenue
32 529
N/A
33 765
+4%
34 059
+1%
35 370
+4%
35 690
+1%
36 417
+2%
36 371
0%
36 748
+1%
37 271
+1%
37 283
+0%
37 984
+2%
38 555
+2%
39 220
+2%
39 703
+1%
39 876
+0%
39 935
+0%
39 567
-1%
40 640
+3%
41 135
+1%
43 053
+5%
44 243
+3%
45 106
+2%
44 991
0%
47 037
+5%
47 773
+2%
48 454
+1%
48 715
+1%
46 758
-4%
45 143
-3%
44 462
-2%
43 464
-2%
43 758
+1%
44 368
+1%
44 451
+0%
45 101
+1%
45 238
+0%
45 844
+1%
45 193
-1%
46 895
+4%
47 395
+1%
47 369
0%
Gross Profit
Cost of Revenue
(26 165)
(26 963)
(26 990)
(27 940)
(28 435)
(29 132)
(29 104)
(29 587)
(29 641)
(29 515)
(30 232)
(30 653)
(31 307)
(31 680)
(31 765)
(31 715)
(31 290)
(32 050)
(32 463)
(34 231)
(35 213)
(35 545)
(35 513)
(36 651)
(37 207)
(37 658)
(37 917)
(35 823)
(34 130)
(33 407)
(32 005)
(32 798)
(33 550)
(34 150)
(34 770)
(35 210)
(35 740)
(35 529)
(37 056)
(37 781)
(38 341)
Gross Profit
6 365
N/A
6 804
+7%
7 068
+4%
7 432
+5%
7 257
-2%
7 286
+0%
7 266
0%
7 160
-1%
7 630
+7%
7 767
+2%
7 752
0%
7 901
+2%
7 911
+0%
8 022
+1%
8 111
+1%
8 220
+1%
8 277
+1%
8 590
+4%
8 671
+1%
8 822
+2%
9 030
+2%
9 561
+6%
9 479
-1%
10 386
+10%
10 566
+2%
10 797
+2%
10 798
+0%
10 935
+1%
11 013
+1%
11 055
+0%
11 459
+4%
10 960
-4%
10 817
-1%
10 301
-5%
10 331
+0%
10 028
-3%
10 104
+1%
9 664
-4%
9 839
+2%
9 614
-2%
9 028
-6%
Operating Income
Operating Expenses
(3 182)
(3 547)
(3 549)
(3 661)
(3 665)
(3 411)
(3 710)
(3 642)
(3 797)
(3 884)
(3 920)
(4 067)
(3 940)
(4 080)
(3 949)
(3 897)
(4 054)
(3 949)
(4 124)
(4 011)
(3 981)
(4 095)
(4 121)
(4 438)
(4 527)
(4 687)
(4 889)
(4 613)
(4 739)
(4 837)
(4 906)
(5 267)
(5 316)
(5 288)
(5 124)
(5 242)
(5 434)
(5 458)
(5 945)
(5 951)
(5 952)
Selling, General & Administrative
(3 190)
(3 553)
(2 243)
(3 663)
(3 667)
(3 416)
(2 348)
(3 604)
(3 761)
(3 846)
(2 442)
(4 057)
(3 929)
(4 068)
(2 308)
(3 901)
(4 058)
(3 954)
(2 393)
(4 012)
(3 982)
(4 096)
(2 613)
(4 443)
(4 532)
(4 693)
(2 718)
(4 607)
(4 732)
(4 828)
(3 004)
(5 264)
(5 314)
(5 287)
(3 082)
(5 241)
(5 433)
(5 457)
(3 431)
(5 952)
(5 952)
Research & Development
0
0
(1 183)
0
0
0
0
0
0
0
(1 267)
0
0
0
(1 523)
0
0
0
(1 609)
0
0
0
(1 401)
0
0
0
(2 033)
0
0
0
(1 749)
0
0
0
(1 865)
0
0
0
(2 349)
0
0
Depreciation & Amortization
0
0
(127)
0
0
0
(148)
0
0
0
(200)
0
0
0
(126)
0
0
0
(123)
0
0
0
(114)
0
0
0
(132)
0
0
0
(152)
0
0
0
(176)
0
0
0
(165)
0
0
Other Operating Expenses
7
6
4
2
1
3
(1 213)
(39)
(37)
(38)
(11)
(10)
(11)
(11)
8
6
5
5
0
0
1
1
6
5
5
6
(6)
(6)
(7)
(9)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
0
1
0
Operating Income
3 182
N/A
3 256
+2%
3 519
+8%
3 769
+7%
3 590
-5%
3 873
+8%
3 556
-8%
3 517
-1%
3 831
+9%
3 882
+1%
3 832
-1%
3 833
+0%
3 970
+4%
3 941
-1%
4 161
+6%
4 322
+4%
4 224
-2%
4 642
+10%
4 547
-2%
4 810
+6%
5 049
+5%
5 466
+8%
5 357
-2%
5 948
+11%
6 040
+2%
6 110
+1%
5 909
-3%
6 322
+7%
6 274
-1%
6 218
-1%
6 553
+5%
5 694
-13%
5 502
-3%
5 013
-9%
5 207
+4%
4 786
-8%
4 670
-2%
4 206
-10%
3 894
-7%
3 663
-6%
3 076
-16%
Pre-Tax Income
Interest Income Expense
(10)
(6)
(10)
17
(1)
68
115
129
46
(21)
(50)
(40)
44
59
49
51
56
75
65
72
179
190
221
201
103
107
128
384
377
358
314
11
(38)
(24)
(113)
(80)
(38)
244
327
860
718
Non-Reccuring Items
(103)
(102)
(170)
(164)
(83)
(76)
(288)
(286)
(280)
(215)
6
27
25
(39)
19
0
56
10
(23)
(37)
(103)
(51)
(18)
(9)
(0)
(6)
(199)
(217)
(325)
(325)
(255)
(235)
(170)
(204)
(26)
(22)
21
46
(31)
(31)
(31)
Gain/Loss on Disposition of Assets
13
13
13
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(3)
0
0
0
(3)
0
0
0
(2)
0
0
0
0
0
0
0
0
0
0
Total Other Income
38
63
21
48
29
8
43
27
33
34
97
90
84
81
34
37
28
35
29
10
30
25
37
36
39
26
39
68
95
116
110
78
36
22
8
14
33
24
28
26
19
Pre-Tax Income
3 120
N/A
3 223
+3%
3 373
+5%
3 670
+9%
3 536
-4%
3 875
+10%
3 426
-12%
3 389
-1%
3 631
+7%
3 680
+1%
3 885
+6%
3 911
+1%
4 125
+5%
4 044
-2%
4 263
+5%
4 411
+3%
4 364
-1%
4 761
+9%
4 619
-3%
4 856
+5%
5 156
+6%
5 630
+9%
5 595
-1%
6 176
+10%
6 182
+0%
6 236
+1%
5 874
-6%
6 556
+12%
6 420
-2%
6 367
-1%
6 720
+6%
5 548
-17%
5 329
-4%
4 807
-10%
5 076
+6%
4 698
-7%
4 686
0%
4 520
-4%
4 218
-7%
4 518
+7%
3 782
-16%
Net Income
Tax Provision
(1 117)
(1 157)
(1 136)
(1 217)
(1 150)
(1 250)
(879)
(848)
(932)
(1 009)
(1 258)
(1 285)
(1 334)
(1 158)
(1 251)
(1 287)
(1 248)
(1 489)
(1 122)
(1 222)
(1 347)
(1 448)
(1 670)
(1 848)
(1 832)
(1 853)
(1 717)
(1 898)
(1 916)
(1 944)
(2 092)
(1 811)
(1 737)
(1 508)
(1 549)
(1 434)
(1 389)
(1 343)
(1 040)
(1 525)
(1 380)
Income from Continuing Operations
2 001
2 064
2 236
2 451
2 384
2 623
2 547
2 538
2 698
2 671
2 627
2 627
2 790
2 885
3 012
3 122
3 116
3 271
3 496
3 634
3 809
4 182
3 925
4 328
4 350
4 383
4 157
4 659
4 504
4 423
4 628
3 737
3 592
3 299
3 527
3 264
3 297
3 177
3 178
2 993
2 402
Income to Minority Interest
8
15
10
16
19
15
19
19
23
26
29
32
29
28
29
25
12
21
17
19
33
22
20
17
16
20
89
91
96
102
40
51
60
51
72
73
92
100
116
236
249
Net Income (Common)
2 011
N/A
2 081
+3%
2 246
+8%
2 469
+10%
2 404
-3%
2 640
+10%
2 566
-3%
2 560
0%
2 723
+6%
2 699
-1%
2 656
-2%
2 658
+0%
2 820
+6%
2 913
+3%
3 042
+4%
3 149
+4%
3 129
-1%
3 293
+5%
3 513
+7%
3 654
+4%
3 842
+5%
4 204
+9%
3 945
-6%
4 346
+10%
4 366
+0%
4 403
+1%
4 246
-4%
4 750
+12%
4 600
-3%
4 525
-2%
4 668
+3%
3 789
-19%
3 653
-4%
3 350
-8%
3 600
+7%
3 337
-7%
3 390
+2%
3 279
-3%
3 295
+0%
3 230
-2%
2 651
-18%
EPS (Diluted)
154.69
N/A
130.06
-16%
183.52
+41%
189.92
+3%
184.92
-3%
203.07
+10%
205.08
+1%
196.92
-4%
209.46
+6%
207.61
-1%
212.26
+2%
204.46
-4%
216.92
+6%
224.07
+3%
243.1
+8%
242.23
0%
250.05
+3%
263.12
+5%
280.75
+7%
291.98
+4%
301.47
+3%
326.57
+8%
307.46
-6%
322.57
+5%
318.32
-1%
321.11
+1%
282.75
-12%
346.39
+23%
333.92
-4%
323.76
-3%
304.9
-6%
263.19
-14%
230.1
-13%
211.99
-8%
227.45
+7%
211.17
-7%
214.5
+2%
208.92
-3%
209.99
+1%
211.2
+1%
173.34
-18%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 242,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.